drugset / Trial / NCT02485015
The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of Apatinib combined with cytokine-induced killer cell (CIK) vs Apatinib as the third line therapy for patients with advanced gastric cancer.
Timeline
- Start
- 2015-06
- Primary completion
- 2030-06
- Completion
- 2033-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CIK cells | Cell therapy | — | — |
| Subject | Rivoceranib | Small molecule | 850 mg | Oral |